Abstract: The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates.

Abstract: The present invention relates to use of the non-secretor/secretor blood group status of an individual as a criterion for need of Lactobacillus/LAB-enriched probiotic supplementation. The present invention relates also to method of assessing the need of an individual for Lactobacillus/LAB-enriched probiotic supplementation by determining the secretory blood group status of the individual.

Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

Abstract: The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAc?3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method.

Abstract: The present invention relates to use of the ABO blood group genotype of an individual as a criterion for microbiota modulation that is tailored based on the differences in the spectrum of bacteria found between individuals with different ABO blood group genotypes. The present invention relates further to a microbial composition tailored based on the microbial genotypes shown to be specific for A, B, and/or O blood groups.

Abstract: The present invention relates to a stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of a proteolytic enzyme in the modification of the cell surface of a stem cell. The present invention further relates to a method of modifying the cell surface of a stem cell by treatment with a proteolytic enzyme.

Abstract: The present invention relates to a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. The present invention further relates to a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.

Abstract: The present invention relates to a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. The present invention further relates to a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.

Abstract: Antibody-saccharide-complexes and methods and uses related to analysis of cells. Also disclosed is a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: A complex of Tra-antibody bound to an isolated glycan comprising type I—N-acetyllactosamine comprising target structure, and methods and uses utilizing said complex.

Abstract: The present invention relates to an in vitro and/or ex vivo method of screening probiotic bacterial strains. The present invention also relates to a method of assessing quality of probiotic culture. In addition, the present invention relates to use of animal cells in screening of a probiotic strain. The present invention also relates to use of animal cells in assessing quality of probiotic culture.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: Provided is a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. Further provided is a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. Further provided is a use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

Abstract: The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates.

Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.

Abstract: Provided is a method for protecting stem cells in a clinical graft against destruction induced by the complement system by adding to the graft at least one factor capable of inhibiting the complement. Also provided is a method for protecting stem cells in a clinical graft against destruction induced by the complement system using a factor capable of inhibiting the complement.

Abstract: Provided is a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. Further provided is a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.

Abstract: Provided is a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. Further provided is a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.

Abstract: The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged.